FDA Statement on risk of cardiovascular events in patients receiving Celebrex

  1. MedWatch - The FDA Safety Information and Adverse Event Reporting Program
    FDA notified healthcare professionals that, based on emerging information,
    including preliminary reports from one of several long term National
    Institutes of Health (NIH) prevention studies, the risk of cardiovascular
    events may be increased in patients receiving Celebrex. FDA is analyzing all
    available information from these studies to determine whether additional
    regulatory action is needed.

    Read the MedWatch 2004 safety summary, including a link to the FDA Statement
    and Drug Information Page at: